Video
Dr Higano explains how the use of ADT in patients with prostat ecancer may impact metabolic and cardiovascular (CV) risk factors, and shares best practices on optimizing risk assessment, mitigation, and monitoring for these factors.
January 2023 AbbVie Inc. Company Confidential
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.